NeuBase Therapeutics NBSE Stock
NeuBase Therapeutics Price Chart
NeuBase Therapeutics NBSE Financial and Trading Overview
| NeuBase Therapeutics stock price | 0.44 USD |
| Previous Close | 3 USD |
| Open | 2.92 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1000 |
| Day's Range | 2.65 - 3.38 USD |
| 52 Week Range | 2.41 - 29 USD |
| Volume | 102.25K USD |
| Avg. Volume | 23.96K USD |
| Market Cap | 91.63M USD |
| Beta (5Y Monthly) | 0.833556 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -18.6 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7 USD |
NBSE Valuation Measures
| Enterprise Value | -3153425 USD |
| Trailing P/E | N/A |
| Forward P/E | -6.0222225 |
| PEG Ratio (5 yr expected) | -0.12 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 6.3466043 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.135 |
Trading Information
NeuBase Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.833556 |
| 52-Week Change | -83.86% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 29 USD |
| 52 Week Low | 2.41 USD |
| 50-Day Moving Average | 3.47 USD |
| 200-Day Moving Average | 4.91 USD |
NBSE Share Statistics
| Avg. Volume (3 month) | 23.96K USD |
| Avg. Daily Volume (10-Days) | 20.2K USD |
| Shares Outstanding | 33.81M |
| Float | 28.22M |
| Short Ratio | 1.32 |
| % Held by Insiders | 13.77% |
| % Held by Institutions | 30.59% |
| Shares Short | 554.76K |
| Short % of Float | 1.76% |
| Short % of Shares Outstanding | 1.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -43.032% |
| Return on Equity (ttm) | -93.46% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -23408468 USD |
| Net Income Avi to Common (ttm) | -24585756 USD |
| Diluted EPS (ttm) | -0.78 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 13.85M USD |
| Total Cash Per Share (mrq) | 0.41 USD |
| Total Debt (mrq) | 5.62M USD |
| Total Debt/Equity (mrq) | 38.9 USD |
| Current Ratio (mrq) | 7.403 |
| Book Value Per Share (mrq) | 0.427 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -24686866 USD |
| Levered Free Cash Flow (ttm) | -15184278 USD |
Profile of NeuBase Therapeutics
| Country | United States |
| State | PA |
| City | Pittsburgh |
| Address | 350 Technology Drive |
| ZIP | 15219 |
| Phone | 412 763 3350 |
| Website | https://www.neubasetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 37 |
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Q&A For NeuBase Therapeutics Stock
What is a current NBSE stock price?
NeuBase Therapeutics NBSE stock price today per share is 0.44 USD.
How to purchase NeuBase Therapeutics stock?
You can buy NBSE shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NeuBase Therapeutics?
The stock symbol or ticker of NeuBase Therapeutics is NBSE.
Which industry does the NeuBase Therapeutics company belong to?
The NeuBase Therapeutics industry is Biotechnology.
How many shares does NeuBase Therapeutics have in circulation?
The max supply of NeuBase Therapeutics shares is 3.75M.
What is NeuBase Therapeutics Price to Earnings Ratio (PE Ratio)?
NeuBase Therapeutics PE Ratio is now.
What was NeuBase Therapeutics earnings per share over the trailing 12 months (TTM)?
NeuBase Therapeutics EPS is -18.6 USD over the trailing 12 months.
Which sector does the NeuBase Therapeutics company belong to?
The NeuBase Therapeutics sector is Healthcare.
NeuBase Therapeutics NBSE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}